Literature DB >> 33291139

Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?

Matthias Totzeck1, Esther Lutgens2,3, Tomas G Neilan4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33291139      PMCID： PMC8088813          DOI： 10.1093/eurheartj/ehaa959

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   35.855


× No keyword cloud information.
  16 in total

1.  Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation.

Authors:  Mariella Bockstahler; Andrea Fischer; Ziya Kaya; Antje Beling; Carl Christoph Goetzke; Hannah Louise Neumaier; Martina Sauter; Meike Kespohl; Anna-Maria Müller; Christin Meckes; Christian Salbach; Mirjam Schenk; Arnd Heuser; Ulf Landmesser; January Weiner; Benjamin Meder; Lorenz Lehmann; Adelheid Kratzer; Karin Klingel; Hugo A Katus
Journal:  Circulation       Date:  2020-03-12       Impact factor: 29.690

2.  Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Joe-Elie Salem; Yves Allenbach; Aurore Vozy; Nicolas Brechot; Douglas B Johnson; Javid J Moslehi; Mathieu Kerneis
Journal:  N Engl J Med       Date:  2019-06-13       Impact factor: 91.245

3.  Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis.

Authors:  Magid Awadalla; Syed S Mahmood; John D Groarke; Malek Z O Hassan; Anju Nohria; Adam Rokicki; Sean P Murphy; Nathaniel D Mercaldo; Lili Zhang; Daniel A Zlotoff; Kerry L Reynolds; Raza M Alvi; Dahlia Banerji; Shiying Liu; Lucie M Heinzerling; Maeve Jones-O'Connor; Rula B Bakar; Justine V Cohen; Michael C Kirchberger; Ryan J Sullivan; Dipti Gupta; Connor P Mulligan; Sachin P Shah; Sarju Ganatra; Muhammad A Rizvi; Gagan Sahni; Carlo G Tocchetti; Donald P Lawrence; Michael Mahmoudi; Richard B Devereux; Brian J Forrestal; Anant Mandawat; Alexander R Lyon; Carol L Chen; Ana Barac; Judy Hung; Paaladinesh Thavendiranathan; Michael H Picard; Franck Thuny; Stephane Ederhy; Michael G Fradley; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2020-02-11       Impact factor: 24.094

4.  Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry.

Authors:  José López-Sendón; Carlos Álvarez-Ortega; Pilar Zamora Auñon; Antonio Buño Soto; Alexander R Lyon; Dimitrios Farmakis; Daniela Cardinale; Miguel Canales Albendea; Jaime Feliu Batlle; Isabel Rodríguez Rodríguez; Olaia Rodríguez Fraga; Ainara Albaladejo; Guiomar Mediavilla; Jose Ramón González-Juanatey; Amparo Martínez Monzonis; Pilar Gómez Prieto; José González-Costello; José María Serrano Antolín; Rosalía Cadenas Chamorro; Teresa López Fernández
Journal:  Eur Heart J       Date:  2020-05-07       Impact factor: 29.983

5.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

6.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

Authors:  Douglas B Johnson; Justin M Balko; Margaret L Compton; Spyridon Chalkias; Joshua Gorham; Yaomin Xu; Mellissa Hicks; Igor Puzanov; Matthew R Alexander; Tyler L Bloomer; Jason R Becker; David A Slosky; Elizabeth J Phillips; Mark A Pilkinton; Laura Craig-Owens; Nina Kola; Gregory Plautz; Daniel S Reshef; Jonathan S Deutsch; Raquel P Deering; Benjamin A Olenchock; Andrew H Lichtman; Dan M Roden; Christine E Seidman; Igor J Koralnik; Jonathan G Seidman; Robert D Hoffman; Janis M Taube; Luis A Diaz; Robert A Anders; Jeffrey A Sosman; Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

7.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.

Authors:  Taku Okazaki; Yoshimasa Tanaka; Ryosuke Nishio; Tamotsu Mitsuiye; Akira Mizoguchi; Jian Wang; Masayoshi Ishida; Hiroshi Hiai; Akira Matsumori; Nagahiro Minato; Tasuku Honjo
Journal:  Nat Med       Date:  2003-11-02       Impact factor: 53.440

8.  Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.

Authors:  Lili Zhang; Daniel A Zlotoff; Magid Awadalla; Syed S Mahmood; Anju Nohria; Malek Z O Hassan; Franck Thuny; Leyre Zubiri; Carol L Chen; Ryan J Sullivan; Raza M Alvi; Adam Rokicki; Sean P Murphy; Maeve Jones-O'Connor; Lucie M Heinzerling; Ana Barac; Brian J Forrestal; Eric H Yang; Dipti Gupta; Michael C Kirchberger; Sachin P Shah; Muhammad A Rizvi; Gagan Sahni; Anant Mandawat; Michael Mahmoudi; Sarju Ganatra; Stephane Ederhy; Eduardo Zatarain-Nicolas; John D Groarke; Carlo G Tocchetti; Alexander R Lyon; Paaladinesh Thavendiranathan; Justine V Cohen; Kerry L Reynolds; Michael G Fradley; Tomas G Neilan
Journal:  Circulation       Date:  2020-06-15       Impact factor: 29.690

9.  Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.

Authors:  Matthias Totzeck; Martin Schuler; Martin Stuschke; Gerd Heusch; Tienush Rassaf
Journal:  Int J Cardiol       Date:  2019-01-11       Impact factor: 4.164

10.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03
View more
  6 in total

1.  Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis.

Authors:  Christoph Rischpler; Tienush Rassaf; Lale Umutlu; Ken Herrmann; Thomas-Wilfried Schlosser; Matthias Totzeck
Journal:  J Nucl Med       Date:  2021-12-02       Impact factor: 11.082

2.  The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.

Authors:  Johann Bauersachs; Rudolf A de Boer; JoAnn Lindenfeld; Biykem Bozkurt
Journal:  Eur Heart J       Date:  2022-02-03       Impact factor: 35.855

Review 3.  Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology.

Authors:  David Kersting; Stephan Settelmeier; Ilektra-Antonia Mavroeidi; Ken Herrmann; Robert Seifert; Christoph Rischpler
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

4.  A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.

Authors:  Nestor Rubio-Infante; Yoel Adbel Ramírez-Flores; Elena Cristina Castillo; Omar Lozano; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Front Cell Dev Biol       Date:  2022-03-30

5.  PD1 Deficiency Modifies Cardiac Immunity during Baseline Conditions and in Reperfused Acute Myocardial Infarction.

Authors:  Lars Michel; Sebastian Korste; Armin Spomer; Ulrike Barbara Hendgen-Cotta; Tienush Rassaf; Matthias Totzeck
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

Review 6.  Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors.

Authors:  Omoruyi Credit Irabor; Nicolas Nelson; Yash Shah; Muneeb Khan Niazi; Spencer Poiset; Eugene Storozynsky; Dinender K Singla; Douglas Craig Hooper; Bo Lu
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.